Holoxan 500 Mg Injection, Holoxan 1G Injection & Holoxan 2 G Injection 500 mg, 1 g or 2 g Injection
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various carcinomas and malignant lymphomas.
Dosage (summary)
Individualized; typically 50-60 mg/kg IV for 5 days or 20-30 mg/kg for 10 days.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated; may cause fetal damage and toxicity in breastfed infants.
Key Drug Interactions
- Increased myelosuppression with other cytostatics
- Increased cardiotoxicity with anthracyclines
- Increased nephrotoxicity with cisplatin
Contraindications
- Hypersensitivity to ifosfamide
- Severely depressed bone marrow function
- Active infections
- Severe renal impairment
- Cystitis
- Pregnancy and lactation
Common side effects
- Myelosuppression
- Nausea
- Vomiting
- Alopecia
- CNS toxicity
Counselling Points
- Hydration is essential during treatment
- Use of Mesna is mandatory to prevent urotoxicity
- Discuss fertility preservation options
Serious warnings
- Risk of severe infections due to immunosuppression
- Potential for secondary malignancies
- CNS toxicity may be fatal
The Holoxan 500 Mg Injection, Holoxan 1G Injection & Holoxan 2 G Injection 500 mg, 1 g or 2 g Injection professional information leaflet below is the property of Baxter Healthcare South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.